Methods for identifying candidate cytotoxic antibody molecules
AssigneeAgency for Science, Technology and Research
InventorBoon Hwa Andre Choo
Life of this patent
Estimating the term…
Abstract
The disclosure relates to methods for screening candidate antibody molecules which bind to podocalyxin-like protein (PODXL) and/or to undifferentiated pluripotent stem cells and particularly, although not exclusively, to methods for identifying candidate cytotoxic antibody molecules.
Claims22
A method of selecting an antibody molecule as a candidate for having cytotoxic activity against a cell which expresses podocalyxin-like protein (PODXL), or is an undifferentiated pluripotent stem cell, wherein the antibody molecule binds PODXL, the method comprising the steps of:
- (i) comparing the binding of a PODXL-binding antibody molecule to a glycan comprising Fucα1-2Galβ1-3GlcNAc with the binding of a non-cytotoxic PODXL-binding antibody molecule to a glycan comprising Fucα1-2Galβ1-3GlcNAc;
- and
- (ii) selecting as a candidate cytotoxic antibody molecule a said PODXL-binding antibody molecule that has a relative binding to said glycan of 30 or more times greater than said non-cytotoxic PODXL-binding antibody molecule.
A method of selecting an antibody molecule as a candidate for having cytotoxic activity against an undifferentiated pluripotent stem cell, or as a candidate for binding PODXL and having cytotoxic activity against a cell which expresses PODXL, the method comprising the steps of:
- (i) comparing the binding of a PODXL-binding antibody molecule to a glycan comprising Fucα1-2Galβ1-3GlcNAc with the binding of a non-cytotoxic PODXL-binding antibody molecule to a glycan comprising Fucα1-2Galβ1-3GlcNAc;
- and
- (ii) selecting as a candidate cytotoxic antibody molecule a said PODXL-binding antibody molecule that has a relative binding to said glycan of 30 or more times greater than said non-cytotoxic PODXL-binding antibody molecule.
A method of selecting an antibody molecule as a candidate for binding PODXL and/or for having cytotoxic activity against a cell which expresses PODXL or is an undifferentiated stem cell, the method comprising selecting an antibody molecule which binds a glycan comprising Fucα1-2Galβ1-3GlcNAc.
A kit of parts comprising:
- (a) a glycan comprising Fucα1-2Galβ1-3GlcNAc;
- (b) an agent that detects binding between the glycan and an antibody molecule;
- and
- (c) a non-cytotoxic control molecule which binds the glycan.
A method of selecting an antibody molecule, from a sample containing such molecules, as a candidate for having cytotoxic activity against an undifferentiated pluripotent stem cell, wherein the antibody molecule binds PODXL, the method comprising the steps of:
- i) contacting the sample of antibody molecules with a plurality of glycans comprising Fucα1-2Galβ1-3GcNAc;
- ii) selecting an antibody molecule having an absolute binding to at least one said glycan in the top 10% as a candidate cytotoxic antibody molecule.
A method of selecting an antibody molecule as a candidate for having cytotoxic activity against an undifferentiated pluripotent stem cell or a cell which expresses podocalyxin-like protein (PODXL), wherein the antibody molecule binds PODXL, the method comprising the steps of:
- (i) measuring the binding of a PODXL-binding antibody molecule to a glycan comprising Fucα1-2Galβ1-3GlcNAc;
- and
- (ii) selecting as a candidate cytotoxic antibody molecule a said PODXL-binding antibody molecule that has a binding to said glycan equal to or greater than that of a cytotoxic PODXL-binding antibody molecule.
A method of selecting an antibody molecule as a candidate for having cytotoxic activity against a cell which expresses podocalyxin-like protein (PODXL) or against an undifferentiated pluripotent stem cell, wherein the antibody molecule binds PODXL, the method comprising the steps of:
- (i) comparing the binding of a PODXL-binding antibody molecule to a glycan comprising Fucα1-2Galβ1-3GlcNAc with the binding of a cytotoxic PODXL-binding antibody molecule to a glycan comprising Fucα1-2Galβ1-3GlcNAc;
- and
- (ii) selecting as a candidate cytotoxic antibody molecule a said PODXL-binding antibody molecule that has a binding to said glycan equal to or greater than that of the said cytotoxic PODXL-binding antibody molecule.
Dependencies are inferred from the claim text.